Viking Therapeutics Clears Mid-Stage NASH Trial

[{"selector":"#anim-853e4682-c43e-4053-8577-e2c8286e4389","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-cf48bdd3-06aa-4023-8579-5c6b408bd294","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

1. Viking Therapeutics' VK2809 achieved a 45.3% decrease in liver fat content in patients with NASH after 12 weeks of treatment.

[{"selector":"#anim-64df64ee-3b80-472d-a249-98f570b2e1f0","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

2. Placebo comparators only experienced a 3.7% drop in liver fat content.

[{"selector":"#anim-28325b40-0ec8-4a4a-9bcf-9394db2a6342","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. VK2809 at 5-mg and 10-mg doses showed reductions of 36.8% and 51.7% in liver fat content, respectively.

[{"selector":"#anim-f50e6625-9611-4f2b-bed2-f346cf25fe14","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

4. The Phase IIb VOYAGE study enrolled 337 patients with biopsy-confirmed NASH and fibrosis.

[{"selector":"#anim-835956ef-e9b7-4a7c-b9e0-0a9c093e8bae","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

5. Treated patients experienced significant placebo-adjusted improvements in low-density lipoprotein cholesterol and triglycerides.

[{"selector":"#anim-8ba476c9-fd56-4c46-852a-3b61da22b736","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. Other atherogenic markers such as apolipoproteins B and C-III also showed significant drops in treated patients.

[{"selector":"#anim-0d070d1a-75e9-4605-80f4-dfb43d715bd4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. VK2809 demonstrated good gastrointestinal tolerability and mostly mild or moderate side effects.

[{"selector":"#anim-244c2b4b-d732-45c3-8154-4a85024f90a2","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. Histology data from VOYAGE is expected in the first half of 2024.

[{"selector":"#anim-f5fa405c-84da-4266-a408-032b020cdb59","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

9. VK2809 is also being evaluated as a treatment for non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

[{"selector":"#anim-5dfc0454-9a90-4625-958c-2fda248acd4c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

10. Viking Therapeutics will continue to analyze data from the study.

[{"selector":"#anim-98ee0b47-0fac-4736-9b4a-3027f25fbd83","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-473e9c28-0ea2-4f8b-a0b8-b24f3320302d","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more